J. Virol., 11 1995, 6609-6617, Vol 69, No. 11
A Trkola, AB Pomales, H Yuan, B Korber, PJ Maddon, GP Allaway, H Katinger, CF Barbas 3rd, DR Burton and DD Ho
We have tested three human monoclonal antibodies (MAbs) IgG1b12, 2G12, and
2F5) to the envelope glycoproteins of human immunodeficiency virus type 1
(HIV-1), and a tetrameric CD4-IgG molecule (CD4-IgG2), for the ability to
neutralize primary HIV-1 isolates from the genetic clades A through F and
from group O. Each of the reagents broadly and potently neutralized B-clade
isolates. The 2F5 MAb and the CD4-IgG2 molecule also neutralized strains
from outside the B clade, with the same breadth and potency that they
showed against B-clade strains. The other two MAbs were able to neutralize
a significant proportion of strains from outside the B clade, although
there was a reduction in their efficacy compared with their activity
against B-clade isolates. Neutralization of isolates by 2F5 correlated with
their possession of the LDKW motif in a segment of gp41 near the
membrane-spanning domain. The other two MAbs and CD4-IgG2 recognize
discontinuous binding sites on gp120, and so no comparison between genetic
sequence and virus neutralization was possible. Our data show that a
vaccine based on the induction of humoral immunity that is broadly active
across the genetic clades is not possible if immunogens that express the
epitopes for MAbs such as 2F5, 2G12, and IgG1b12 in immunogenic
configurations can be created. Furthermore, if the three MAbs and CD4-IgG2
produce clinical benefit in immunotherapeutic trials in the United States
or Europe, they may also do so elsewhere in the world.
Copyright © 1995, American Society for Microbiology
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|